Diagnosis of heparin-induced delayed type hypersensitivity

Phlebologie

Volumn 39, Issue 4, 2010, Pages 226-231

  Schindewolf, M ^a   Ludwig, Ralf J ^b   Wolter, M ^a   Hardt, K ^a   Kaufmann, R ^a   Lindhoff Last, E ^a   Boehncke, W H ^a   Kahle, B ^b  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Adverse event; Allergy; Delayed type hypersensitivity; Heparin; Heparin induced thrombocytopenia type II; Type IV allergic reaction

Indexed keywords

DALTEPARIN; DANAPAROID; ENOXAPARIN; FONDAPARINUX; HEPARIN; HEPARIN CALCIUM; HEPARINOID; LOW MOLECULAR WEIGHT HEPARIN; MONOEMBOLEX; NADROPARIN; TINZAPARIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DELAYED HYPERSENSITIVITY; DRUG INDUCED DISEASE; FEMALE; HEPARIN INDUCED DELAYED TYPE HYPERSENSITIVITY; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; INTRACUTANEOUS TEST; MALE; PATCH TEST; PRICK TEST; PROVOCATION TEST; SENSITIVITY AND SPECIFICITY; SKIN BIOPSY; SKIN DEFECT;

EID: 77957345648     PISSN: 0939978X     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1622313     Document Type: Article

References (24)

1. Alban S. From heparins to factor Xa inhibitors and beyond. Eur J Clin Invest 2005; 35 (Supp I): 12-20.
2. Neykova A, Tzvetkov B, Merah AK, Matheron C, Kirsch M. The HIT treatment in a cardiac surgery patient. Int J Cardiol 2009; doi: 10.1016/j.ijcard.2009.03. 027
3. Berkun Y, Haviv YS, Schwartz LB, Shalit M. Heparin- induced recurrent anaphylaxis. Clin Exp Allergy 2004; 34: 1916-1918.
4. Bircher AJ, Harr T, Hohenstein L, Tsakiris DA. Hypersensitivity reactions to anticoagulant drugs: diagnosis and management options. Allergy 2006; 61: 1432-1440.
5. Efird LE, Kockler DR. Fondaparinux for thromboembolic treatment and prophylaxis of heparininduced thrombocytopenia. Ann Pharmacother 2006; 40: 1383-1387.
6. Eichler P, Budde U, Haas S, Kroll H, Loreth RM, Meyer O et al. First workshop for detection of heparin- induced antibodies: validation of the heparininduced platelet-activation test (HIPA) in comparison with a PF4/heparin ELISA. Thromb Haemost 1999; 81: 625-629.
7. Gaigl Z, Pfeuffer P, Raith P, Brocker EB, Trautmann A. Tolerance to intravenous heparin in patients with delayed-type hypersensitivity to heparins: a prospective study. Br J Haematol 2005; 128: 389-392.
8. Grassegger A, Fritsch P, Reider N. Delayed-type hypersensitivity and cross-reactivity to heparins and danaparoid: a prospective study. Dermatol Surg 2001; 27: 47-52.
9. Komericki P, Grims RH, Kränke B, Aberer W. Acute generalized exanthematous pustolosis from dalteparin. J Am Acad Dermatol 2007; 57: 718-721.
10. Lopez S, Torres MJ, Rodriguez-Pena R, Blanca- Lopez N, Fernandez TD, Antunez C et al. Lymphocyte proliferation response in patients with delayed hypersensitivity reactions to heparins. Br J Dermatol 2009; 160: 259-265.
11. Ludwig RJ, Schindewolf M, Utikal J, Lindhoff-Last E, Boehncke WH. Management of cutaneous type IV hypersensitivity reactions induced by heparin. Thromb Haemost 2006; 96: 611-617.
12. Ludwig RJ, Schindewolf M, Alban S, Kaufmann R, Lindhoff-Last E, Boehncke WH. Molecular weight determines the frequency of delayed type hypersensitivity reactions to heparin and synthetic oligosaccharides. Thromb Haemost 2005; 94: 1265-1269.
13. Ludwig RJ, Schindewolf M, Lindhoff-Last E, Boehncke WH. The influence of heparin's molecular weight and the incidence of delayed type hypersensitivity reactions revisited; in response to Grims et al. Br J Dermatol 2008; 158: 849-851
14. O'Meara AC, Demarmels BF, Heizmann M. Fondaparinux as an alternative therapy in heparin-induced delayed-type hypersensitivity skin lesions. Thromb Haemost 2007; 98: 1389-1391.
15. Schindewolf M, Schwaner S, Wolter M, Kroll H, Kaufmann R, Boehncke WH et al. Incidence and causes of heparin-induced skin lesions. Can Med Assoc J 2009; 181: 477-481.
16. Schindewolf M, Ludwig RJ, Wolter M, Himsel A, Zgouras D, Kaufmann R et al. Tolerance of fondaparinux in patients with generalized contact dermatitis to heparin. J Eur Acad Dermatol Venereol 2008; 22: 378-80.
17. Schindewolf M, Luxembourg B, Lindhoff-Last E. Use of fondaparinux in patients with heparin-induced thrombocytopenia type II. Vasa 2006; 35 (Suppl 69): 70.
18. Schindewolf M, Kahle B, Lindhoff-Last E, Ludwig RJ. Heparin-induced skin lesions: More common than suspected. Phlebologie 2010; 39: 5-11.
19. Schindewolf M, Kroll H, Ackermann H, Garbaraviciene J, Kaufmann R, Boehncke WH, Ludwig RJ, Lindhoff-Last E. Heparin-induced non-necrotizing skin lesions: rarely associated with heparin-induced thrombocytopenia. J Thromb Haemost 2010; doi 10.1111/j.1538-7836.2010.03795.x.
20. Singh S, Verma M, Bahekar A, Agrawal P, Duggal J, Ilescu M, et al. Enoxaparin-induced skin necrosis: a fatal outcome. Am J Ther 2007; 14: 408-410.
21. Uncu H. A comparison of low-molecular-weight heparin and combined therapy of low-molecularweight heparin with an anti-inflammatory agent in the treatment of superficial vein thrombosis. Phlebology 2009; 24: 56-60.
22. Utikal J, Peitsch WK, Booken D, Velten F, Dempfle CE, Goerdt S et al. Hypersensitivity to the pentasaccharide fondaparinux in patients with delayed-type heparin allergy. Thromb Haemost 2005; 94: 895-896.
23. Warkentin TE, Roberts RS, Hirsh J, Kelton JG. Heparin- induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a nested cohort study. Chest 2005; 127: 1857-1861.
24. Whitehead ME, Fitzwater JE, Lindley SK, Kern SB, Ulirsch RC, Winecoff WF, III. Quality assurance of histopathologic diagnoses: a prospective audit of three thousand cases. Am J Clin Pathol 1984; 81: 487-491.